The effects observed with trametinib in combination with CQ were not limited to pancreatic cancer; patient-derived xenografts (PDX) of other tumors, including NRAS-mutated melanoma and BRAF-mutated colorectal cancer, showed similar responses. Here, BRAF is linked to melanoma.